Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2146-2149

  Betuela, Inoni ^a   Bassat, Quique ^b   Kiniboro, Benson ^a   Robinson, Leanne J ^a,c   Rosanas Urgell, Anna ^a,b   Stanisic, Danielle ^a,c   Siba, Peter M ^a   Alonso, Pedro L ^b   Mueller, Ivo ^a,b,c  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CHLOROQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PLUSONERMIN; PRIMAQUINE;

ARTICLE; CHEST TIGHTNESS; CHILD; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; NAUSEA; OTALGIA; PAPUA NEW GUINEA; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SCLERA DISEASE; SIDE EFFECT; STOMACH PAIN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

AGING; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; COHORT STUDIES; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBINS; HUMANS; INFANT; MALARIA; MALARIA, FALCIPARUM; MALARIA, VIVAX; MALE; NEW GUINEA; PRIMAQUINE;

EID: 84858675337     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05566-11     Document Type: Article

References (12)

1. Baird JK, Hoffman SL. 2004. Primaquine therapy for malaria. Clin. Infect. Dis. 39:1336-1345. (Pubitemid 39458520)
2. Baird JK, Rieckmann KH. 2003. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 19:115-120. (Pubitemid 36338074)
3. Cappellini MD, Fiorelli G. 2008. Glucose-6-phosphate dehydrogenase deficiency. Lancet 371:64-74.
4. Clayman CB, et al. 1952. Toxicity of primaquine in Caucasians. JAMA 149:1563-1568.
5. Fryauff DJ, et al. 1995. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 346:1190-1193.
6. Genton B, et al. 2008. Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med. 5:e127.
7. Karyana M, et al. 2008. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar. J. 7:148.
8. Lin E, et al. 2010. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One 5:e9047.
9. Mueller I, et al. 2009. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malar. J. 8:41.
10. Shekalaghe SA, et al. 2010. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob. Agents Chemother. 54:1762-1768.
11. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who. int/publications/2010/9789241547925-eng.pdf.
12. Youngster I, et al. 2010. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf. 33:713-726.